氨甲环酸对成人孤立性创伤性脑损伤的疗效:一项多中心回顾性研究
该多中心回顾性横断面研究利用日本创伤数据库2019–2023年数据,纳入年龄≥18岁、无颅外损伤、伤后3小时内完成CT的孤立性TBI患者5732例,主分析纳入5639例。采用倾向性评分逆概率加权(IPTW)校正后,氨甲环酸与住院死亡率(aOR 0.82;95%CI 0.66–1.01)及不良神经功能结局(aOR 1.01;95%CI 0.79–1.30)均无显著关联。按TBI严重程度分层后,仅重型TBI(GCS 3–8)患者中氨甲环酸组住院死亡率显著降低(aOR 0.78;95%CI 0.63–0.97)。结论认为氨甲环酸仅与孤立性重型TBI患者死亡率降低相关。
要点
- 在孤立性TBI总体人群中,IPTW校正后氨甲环酸与住院死亡率无显著关联(aOR 0.82;95%CI 0.66–1.01)。
- 氨甲环酸与出院时不良神经功能结局(Glasgow结局量表评分1–3)无显著关联(aOR 1.01;95%CI 0.79–1.30)。
- 按GCS分层,仅重型TBI(GCS 3–8)患者中氨甲环酸组住院死亡率显著降低(aOR 0.78;95%CI 0.63–0.97)。
- 轻中型TBI患者中未观察到氨甲环酸与住院死亡率的显著关联。
- 研究为多中心回顾性横断面设计,采用倾向性评分IPTW校正混杂。
适用人群与场景
- 年龄≥18岁的创伤性脑损伤患者,且不合并颅外损伤(孤立性TBI)。
- 伤后3小时内完成计算机断层扫描(CT)成像。
- 数据来源为日本创伤数据库(Japan Trauma Data Bank)2019年至2023年收治患者。
诊断标准与关键阈值
- TBI严重程度按格拉斯哥昏迷量表(GCS)评分分类:重型3–8分,中型9–12分,轻型13–15分。
- 不良神经功能结局定义为出院时Glasgow结局量表(Glasgow Outcome Scale)评分1–3分。
研究设计与关键结果
- 研究类型为多中心、回顾性、横断面研究,使用日本创伤数据库2019–2023年数据,共纳入5732例患者,主分析纳入5639例(排除变量缺失者)。
- 主要终点为住院死亡率:IPTW校正后氨甲环酸组与对照组无显著差异(aOR 0.82;95%CI 0.66–1.01)。
- 次要终点为出院时不良神经功能结局(Glasgow结局量表评分1–3):IPTW校正后无显著关联(aOR 1.01;95%CI 0.79–1.30)。
- 按TBI严重程度亚组分析:仅重型TBI(GCS 3–8)患者中氨甲环酸组住院死亡率显著低于对照组(aOR 0.78;95%CI 0.63–0.97)。
- 中型和轻型TBI亚组中,氨甲环酸与住院死亡率的关联未达统计学显著。
证据类型、等级与局限
- 证据类型:多中心回顾性横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于孤立性重型TBI(GCS 3–8)患者,氨甲环酸可能与住院死亡率降低相关(aOR 0.78;95%CI 0.63–0.97),作者结论认为氨甲环酸仅与孤立性重型TBI患者死亡率降低相关。
- 对于孤立性轻型或中型TBI患者,本研究未观察到氨甲环酸与住院死亡率或神经功能结局的显著关联。
- 本研究为回顾性观察性设计,结果提示的关联不能直接等同于因果关系。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the association between tranexamic acid (TXA) and neurological outcome, including mortality, in isolated traumatic brain injury (TBI), considering the severity of TBI.
METHODS: This multicenter, retrospective, cross-sectional study was conducted using Japan Trauma Data Bank from 2019 to 2023. Patients aged ≥18 years with TBI not complicated by extracranial injury who underwent computed tomography imaging within 3 h of injury were included. The primary outcome was in-hospital mortality and the secondary outcome was poor neurological outcome at hospital discharge, defined as a Glasgow Outcome Scale score of 1-3. The association between TXA administration and clinical outcomes was assessed using logistic regression adjusted by propensity score-based inverse probability of treatment weighting (IPTW). TBI severity was classified using the Glasgow Coma Scale scores as severe (3-8), moderate (9-12), or mild (13-15) to further evaluate the outcomes.
RESULTS: During the study period, 5732 patients were included, and the main analysis was conducted on 5639 patients excluding those with missing valiables. After IPTW, TXA was not associated with in-hospital mortality (adjusted odds ratio [aOR], 0.82; 95 % confidence interval [CI], 0.66-1.01) nor poor neurological outcome (aOR, 1.01; 95 % CI, 0.79-1.30). In the subgroup analysis according to TBI severity, in-hospital mortality was significantly lower in the TXA group only in patients with severe TBI (aOR, 0.78; 95 % CI, 0.63-0.97).
CONCLUSIONS: Our study found that TXA is associated with reduced mortality only in patients with isolated severe TBI.
参考来源
- Utsumi S, Ohki S, Shime N, et al. Efficacy of tranexamic acid in adult isolated traumatic brain injury: A multicenter retrospective study. Am J Emerg Med. 2025. PMID: 40479948. doi:10.1016/j.ajem.2025.05.030
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。